Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now. With a first-in-class nod, the FDA has cleared Yescarta, a …
Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …
Novartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb …
After two years of meager sales for Polivy, Roche is trumpeting a much-coveted clinical win that could open up a blockbuster market for the drug. …
Xynomic Pharma announced it has completed a new Series B financing round and now will initiate eight clinical trials, four of which are for different types of …
Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
